Thrilled to share our story out in Cancer Cell, led by the amazing Kay Hanggi (now on the job market). We show that necrotic forms of cell death and the subsequent release of IL1a drives myeloid-based immune suppression in models of breast cancer. (1/11) cell.com/cancer-cell/abstrac…

Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity dlvr.it/TGhVzG

Excited to share our latest by @Triantafyllia14 where we find that IFNg acts as a metabolic switch to prune tumor-associated lymphangiogenesis and unlink immune surveillance and metastasis biorxiv.org/content/10.1101/… #theLundLab

#ScienceSaturday ➡️ Did you know that some chemotherapies can enhance the immune response against #cancer?   ❓ How might we potentiate this?   ➡️ @Ruffell_Lab and colleagues from @moffittnews found that the necrotic cell death induced by #chemotherapy releases IL-1 alpha which induces immunosuppressive myeloid cells. Inhibiting IL-1 alpha in combination with chemotherapy enhanced antitumor responses. ‼️ This may be a promising approach for future clinical trials. 🔗 Here’s a link to the full study- cell.com/cancer-cell/abstrac… @Cancer_Cell

People, the IL-1 pathway is SO RELEVANT in cancer 🔥🔥 IL-1a released from dying tumor cells dampens anti-tumor immunity by recruiting immune suppressive myeloid cells - this limits efficacy of chemo and ICB by Brian Ruffel in @Cancer_Cell cell.com/cancer-cell/fulltex…

Online Now: Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity dlvr.it/TGJwxg

Check out our latest paper “Differentiation fate of a stem-like CD4 T cell control immunity to cancer”, led by @Maria_Carden1 now live @Nature tinyurl.com/33d24k89 . This work examines how CD4 T cell differentiation dictates the outcome of the cancer response. Thread below

Our new study published today @Nature uncovers that Transgelin 2 preserves T cell lipid metabolism and anti-tumor activity. Transgelin 2 is silenced in dysfunctional TILs, and restoring its expression enhances CAR-T cell therapy in #OvarianCancer 👇nature.com/articles/s41586-0…

Congratulations Dr. Liu @SitemanCenter and collaborators @LabBeatty and K.Bryant on their featured article in @ScienceTM . And HUDGE THANKS to @PanCAN for bringing this team together and funding the trial that came out of the science with @verastemoncology.

Our review on a topic we eagerly enjoy exploring in the lab- how our fav immune cell types influence/are influenced by metabolic disorders preceding cancer- so much to learn! 👏🏻👏🏻 to #DanielTaranto for leading the effort, to @djkloosterman and the whole lab for their input! 🔥🔥